KdT Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inJonathan Sheena(Director)
Board seatCain McClary· per SEC Form D
Co-investorsACVC PartnersAndreessen HorowitzRaptor GroupTriatomic CapitalAME Cloud VenturesDigitalis Ventures+1 more
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)
BoardJacob Robinson(Co-founder & CEO)in
Co-investorsArboretum VenturesPsyMed VenturesTMC Venture FundCapital FactoryDivergent CapitalDolby Family Ventures+2 more
ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.
BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US
Harshal Chokhawala(Founder & CEO)
Co-investorsAccelr8Breakout LabsBreakout VenturesCavallo VenturesDudley FundFreshTracks Capital+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.